Lab21 hires cfo
Susan Lowther joins Cambridge, UK-based firm
Lowther has spent more than 20 years in the pharmaceutical, biotech and healthcare industries and has held senior management positions at BioWisdom, RiboTargets, Lonza Biologics, Celltech and Monsanto.
Graham Mullis, Lab21 ceo, said: ‘Susan’s financial and life sciences industry expertise, particularly in the area of acquisitions, will be essential as we continue to develop the company.’
You may also like
Finance
![Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network]()
Ofichem acquires US drug substance CDMO Kinentia Biosciences to expand transatlantic network
The company has agreed to acquire New York-based Kinentia Biosciences, expanding its US presence and combining Kinentia’s early-stage development expertise with Ofichem’s European drug substance development and GMP manufacturing capabilities
Design & Build
![Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics]()
Agilent expands Boulder facility with dedicated enzymatic ligation laboratory for oligonucleotide therapeutics
The new space complements established solid-phase synthesis operations, giving Agilent's Advanced Therapeutics Division a dedicated environment to develop solvent-free enzymatic manufacturing approaches as oligonucleotide pipeline demand grows
Manufacturing
![Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month]()
Piramal Pharma Solutions and NP2 to complete cyclophosphamide development phase next month
Piramal Pharma Solutions (“PPS”), a leading global Contract Development and Manufacturing Organisation (CDMO) and part of Piramal Pharma Ltd. (“PPL”) (NSE: PPLPHARMA | BSE: 543635), and its partner NP2, a nonprofit generic drug manufacturer, today announced their plans to finish the drug development phase of the generic cancer drug cyclophosphamide in October
